Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Test-and-treat strategies for regional elimination of lymphatic filariasis
ISRCTN15320064Phase 3Active, not recruiting
- Sponsor
- Kumasi Centre for Collaborative Research in Tropical Medicine
- Start
- Dec 2024
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, open-label trial of doxycycline, moxidectin, albendazole and ivermectin in filariasis (3 arms), sponsored by Kumasi Centre for Collaborative Research in Tropical Medicine. Primary endpoint: Percentage of CFA-negative eligible participants at 24 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
doxycyclinemoxidectinalbendazoleivermectin
03
Conditions
filariasis
Beyond the preview
Go deeper on ISRCTN15320064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15320064.